Interim Results
14/03/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220314:nRSN5840Ea&default-theme=true
RNS Number : 5840E Craneware plc 14 March 2022
Craneware plc
("Craneware" or the "Company" or the "Group")
Interim Results of newly scaled Business
Strong growth and expanded market opportunity
14 March 2022 - Craneware (AIM: CRW.L), the market leader in Value Cycle
solutions for the US healthcare market, is pleased to announce its unaudited
results for the six months ended 31 December 2021 (H1 FY22).
Financial Highlights (US dollars)
· First interim update for the enlarged Group, following the acquisition of
Sentry Data Systems Inc ("Sentry")
· Revenue for the six months increased 111% to $80.2m (H1 2021: $38m)
· Adjusted EBITDA(1) increased 78% to $23.7m (H1 2021: $13.3m)
· Adjusted profit before tax(2) increased 68% to $17.1m (H1 2021: $10.2m)
· Profit before tax decreased to $6.2m (H1 2021: $9.9m) after $8.9m of
amortisation of acquired intangible assets (H1 2021: $0m) and exceptional
costs of $1.9m (H1 2021: $0.3m)
· Adjusted basic EPS(3) increased 34% to 43.5 cents per share (H1 2021: 32.5
cents per share)
· Annual Recurring Revenue(4) reached a new record of approximately $165m (30
June 2021: $64.5m)
· Cash of $41.7m, excluding restricted cash of $9.3m (H1 2021: $50.7m)
· Net debt of $72.9m after the acquisition of Sentry
· Interim dividend increased 4% to 12.5p per share (H1 2021: 12p per share)
· Investment in R&D and innovation of $21.6m (H1 2021: $11.6m) of which
$6.8m, being 31% has been capitalised (H1 2021: $4.5m, 39%)
1 Adjusted EBITDA refers to earnings before interest, tax,
depreciation, amortisation, share based payments and acquisition and share
transaction related costs.
2 Adjusted profit before tax refers to profit before tax,,
amortisation of acquired intangibles and acquisition and share transaction
related costs.
3 Adjusted Earnings per share (EPS) calculations allow for
the tax adjusted acquisition costs and share related transactions together
with amortisation on acquired intangible assets
4 Annual Recurring Revenue includes the annual value of
licence and transaction revenues as at 31 December 2021 that are subject to
underlying contracts
Operational Highlights
· Acquisition of Sentry completed 12 July 2021
· First cross-group sales achieved
· Integration of Sentry progressing ahead of plan
· Increase of 26% to 1,134 hospitals on the Trisus Platform
· Transition to a Cloud-based offering on track for completion by the end of
this calendar year
· % of ARR from the Cloud increased to 67% (30 June 2021: 16%)
· Organic software licence revenue growth, contributing to the strong growth in
ARR
· Professional services delivery impacted due to COVID 19 related headwinds in
the period
Outlook
· Strong progress across all areas of the enlarged Group positions the business
well for accelerated growth
· Cross-sell opportunity provides potential for further accelerated ARR Growth
· The Group remains well capitalised with cash reserves of $41.7m and net debt
of $72.9m
· The Board's expectations for the full year ending 30 June 2022 remain
unchanged
Keith Neilson, CEO of Craneware commented,
"The combined scale and expertise of the enlarged Craneware Group provides the
potential for acceleration in ARR growth over the medium term, as we unlock
the considerable cross and upsell opportunities within our enlarged customer
base. Through our increased sales and marketing operations and unique breadth
of offering we are also well placed to secure increased market share as the US
healthcare industry continues its drive towards achieving greater value in
healthcare.
"Whilst remaining cognisant of the challenges our customers continue to face;
the Group remains on-course to deliver results for the current year in line
with management's expectations.
"With a strong balance sheet, high levels of recurring revenues, high customer
retention rates and an ARR of $165m as at 31 December 2021, we have a strong
financial foundation from which to accelerate growth and investment to fulfil
our potential, thereby increasing shareholder value.
"We are delighted to see our first cross-sales within the enlarged Group,
which we expect to accelerate once the COVID 19 headwinds fully dissipate.
With an expanded opportunity we look to the future with considerable
excitement and confidence as we work as one team to transform the business of
US healthcare."
For further information, please contact:
Craneware plc +44 (0)131 550 3100
Keith Neilson, CEO
Craig Preston, CFO
Alma (Financial PR) +44 (0)20 3405 0205
Caroline Forde, Hilary Buchanan, Joe Pederzolli craneware@almapr.co.uk
Peel Hunt (NOMAD and Joint Broker) +44 (0)20 7418 8900
Dan Webster, Andrew Clark
Investec Bank PLC (Joint Broker) +44 (0)20 7597 5970
Patrick Robb, Henry Reast, Sebastian Lawrence
( )
Berenberg (Joint Broker) +44 (0)20 3207 7800
Mark Whitmore, Richard Andrews, Alix Mecklenburg-Solodkoff
About Craneware
We at the Craneware Group of companies, including our latest additions Sentry
Data Systems and Agilum Healthcare Intelligence, passionately believe we can
impact healthcare profoundly by delivering the insights healthcare
organizations need to also transform the business of healthcare. Our shared
vision is to be the operational and financial partner for U.S. healthcare
providers.
Our combined suite of applications and industry-leading team of experts help
our customers contextualize operational, financial, and clinical data,
providing insights that clearly demonstrate what great looks like. These value
cycle insights deliver revenue integrity and 340B compliance, as well as
margin and operational intelligence - something no other single partner can
provide.
Together, approximately 40% of registered U.S. hospitals are now our
customers, including more than 2,000 U.S hospitals and health systems and
almost 10,000 clinics and affiliated retail pharmacies. Our customers are
operating with a financial impact of nearly half a trillion dollars. We have
data sets from customers covering more than 150 million unique patients
encounters.
Learn more at www.craneware.com (http://www.craneware.com)
Chairman's Statement
I am delighted to report on a period of positive financial and strategic
progress. The Group delivered organic growth in software licence revenue in
the period whilst having made significant progress in the integration of the
newly acquired Sentry business. This paves the way for long-term sustained
acceleration as COVID 19 related impediments dissipate and the Group unlocks
the significant cross-sell opportunities across the enlarged customer base and
the broader market.
Annual Recurring Revenue growth provides strong platform
This is the first reporting period of the enlarged Craneware Group, following
the acquisition of Sentry Data Systems Inc ("Sentry") on 12 July 2021 and the
results demonstrate the increased scale of the business. Group Revenues
increased 111% to $80.2m with an adjusted EBITDA increase of 78% to $23.7m.
Annual Recurring Revenue(1) grew ahead of management's expectations in the
period to a new milestone of approximately $165m (30 June 2021: $64.5m).
Customer retention rates remain high, at above 90% across the Group. The Group
maintains healthy cash reserves of $41.7m, excluding restricted cash of $9.3m
and a net debt of $72.9m after the acquisition of Sentry and the associated
acquisition costs, in line with the Board's expectations. These amounts are
after the return of $7.2m (H1 2021: $5.3m) to shareholders through dividends,
the investment in R&D of $21.6m (H1 2021: $11.6m) and debt repayment of
$4m (H1 2021: $0).
Supportive market drivers
The long-term drivers for the adoption of Craneware's software continue to
strengthen. US healthcare providers face pressure from increasing regulation,
competition, pharmacy costs and patient expectations and are struggling to
manage the enormity and complexity of their operational cost bases. Meanwhile
both Republicans and Democrats have previously expressed their desire for
healthcare reform and the industry widely anticipates that reform will remain
a key agenda point moving forward, with the drive to derive greater value from
healthcare sitting at its heart.
With over 20 years of healthcare data powering our Trisus platform, we are
uniquely positioned to provide the insights our customers need to manage their
operations more efficiently and mitigate risk while delivering increased
levels of care. Importantly, in the period Craneware Group customers have seen
in excess of a $0.5 billion in benefit from utilising our 340B solutions,
helping to stretch scarce federal resources as far as possible, reach more
eligible patients and provide more comprehensive services.
This tangible positive impact our solutions can make on the lives of others
continues to be a great motivator for our talented team. We have been
delighted to welcome the Sentry and Agilum teams into the Craneware Group and
on behalf of the Board, I would like to thank all the enlarged team for their
continued passion and commitment.
Investment in innovation provides increased addressable opportunity
Our investment in innovation and M&A strategy provide us with a growing
solution set to cross-sell into our customers and with nearly 40% of all US
hospitals and over 10,000 clinics and affiliated retail pharmacies as
customers, we have an enviable position within the industry. We have seen our
average annual hospital contract value increase 60% in the last five years,
demonstrating the success of this strategy, with considerable room for further
growth. While we may see fluctuations in our professional services revenue in
any individual reporting period, our largely recurring revenue business model
provides us with the revenue visibility to continue to invest in our people
and offering, to capitalise on the significant opportunity.
Positive Outlook
We continue to benefit from high operating margins and strong cash flow
conversion, and with considerably increased scale and an exit rate of Annual
Recurring Revenues at the end of the period of $165m, whilst remaining
cognisant of the challenges our customers continue to face, we look to the
future with confidence.
Will Whitehorn
Chair Craneware plc
14 March 2022
Strategic Report
The acquisition of Sentry, which completed in the first month of the fiscal
year was a landmark moment in the history of Craneware, significantly
strengthening the Group's pharmacy offering, adding customers, products and
expertise, while expanding our datasets and providing us with a considerable
cross-sale opportunity.
Just a few months post-acquisition, we are seeing exciting signs of what can
be achieved, with the first three cross-sales into the existing customer base
secured, demonstrating the potential value of cross-sales into the extensive
existing customer base. As we look across the Group, we see an energised,
cohesive team, all united in the shared mission to transform the business of
US healthcare.
Alongside the integration work, we continue to make considerable progress in
our transition to a cloud-based offering, with the migration of our customers
to the Trisus platform on track for completion by the end of this calendar
year. Once on the platform, we are seeing customers respond positively to the
increased insights it provides, providing for further upsell opportunities. We
are pleased to confirm that the level of sales of Trisus applications already
covers 70% of the amount of capitalised R&D spent on the platform and
Trisus applications development to date, underwriting the quality of the
investment made.
Following a brief time of respite through the summer months, managing the
impact of the COVID 19 pandemic and the related fallout, once again became the
top priority for all healthcare-related organisations during the period. Our
customers continue to be on the front-line, and we are committed to doing all
we can both now and into the future, to ensure they have the financial and
operational strength to withstand this wave and any future challenges. While
this has had a short-term impact on our ability to be on customer site, and
therefore our ability to deliver professional services, the successes achieved
prior to the Omicron wave give us confidence in our ability to increase our
revenue growth in future periods.
Our customers continue to take steps to create further resilience across their
financial operations. We are committed to partnering with them by providing
the platform, regulatory information and data to enable them to do so. We
believe both the Group and our customer base are strongly placed to deal with
the future impacts of the pandemic and for our products to be part of the
solution in terms of helping hospital preparedness.
Growth Strategy - innovation to profoundly impact US healthcare operations
which will drive demand and expand our addressable market.
To date, our growth has been driven through increases in market share and
product set penetration (land and expand). In recent years, we have invested
in the development of the Trisus platform; a sophisticated cloud data
aggregation and intelligence platform which will be the foundation as we
migrate our existing products to the cloud, leverage our data assets to expand
our offering, integrate third party solutions to the platform and benefit from
the scalability of cloud-technology.
While other platforms have been designed to address the clinical side of a
hospital, from a competitive positioning perspective, we have created the
market's only platform that addresses, the breadth of the value cycle, aiming
to solve inefficiencies and waste across operational, administrative and
financial functions of a hospital. Through the acquisition of Sentry, we have
created considerable distance between us and other point solution vendors, in
terms of depth of data, breadth of offering, size of customer base and scale
of operations, significantly increasing our ability to serve what is a growing
and sustainable, long-term addressable market.
Integration of Sentry Data Systems, Inc. and new management structure
Sentry Data Systems, Inc. is a leader in pharmacy procurement, compliance and
utilisation management. The successful conclusion of the acquisition marks a
transformational point in our journey, considerably expanding our customer
base, data sets, product offering and market presence.
The acquisition enhances one of our focus areas; pharmacy operations within
healthcare providers. Pharmacy is the largest cost area for US hospitals apart
from staff costs and the acquisition of Sentry extends the intelligence of our
Pharmacy product family to hospital affiliated retail and contract specialty
pharmacies. We see significant cross-selling opportunities through the
complementary nature of Sentry's product suite and customer base.
We were delighted to secure cross-sales in each of the three main categories
of cross-sell following the acquisition of Sentry, being both sales of Sentry
and sales of Craneware products to each other's historic customer base as well
as expansion sales to historical joint customers.
The integration of Sentry continues to progress ahead of plan, with the
integration of the management teams and associated operational departments
nearing completion and the sales and technology teams on target to be fully
integrated by the end of the current financial year. The benefits of the
Group's increased scale are now being seen in greater operational efficiencies
across areas such as supply chain, office space and product development and a
considerably enlarged sales and marketing team. We remain on track to
achieve the cost synergies anticipated, and while an element of these
synergies will be reinvested into the workforce, we anticipate overall the
same level to ultimately be achieved as forecast, with an early target of
returning to an overall EBITDA margin of 30%.
We have formed one combined management team, including a new role of
Transformation Officer, to oversee the continued evolution of the Craneware
Group with our commitment to a lean operating model.
New & Expanded KPIs
Following the acquisition of Sentry, and increasing standardisation in how
SaaS companies report, we are introducing new and expanded KPIs, to
demonstrate the delivery against the growth strategy and to allow easier
comparison between the Group and its peers.
For H1 FY22 these are:
· Annual Recurring Revenue (ARR)
· % ARR from the Cloud
· Adjusted Earnings before Interest Tax, Depreciation and
Amortisation (Adj. EBITDA)
· Adjusted EBITDA Margin (Adj. EBITDA %)
· Operating Cash conversion percentage
· Net debt
· Revenue Growth
This current list of KPI's is not thought to be exhaustive but a starting
point to build on. We intend to add further SaaS KPI's to this list, in
particular those that require twelve month financials, alongside the full year
results later this year.
Three Growth Pillars
Our growth strategy has three fundamental growth pillars:
1. The transition of our customers to cloud-based versions of our existing
on-premise solutions, to act as a gateway to the benefits and additional
applications on the Trisus platform.
We now have 1,134 hospitals on our Trisus platform, an increase of 26% over
the last six months, with their flow of data adding to our valuable data lake.
Having already transitioned some of our smaller offerings onto the Trisus
platform, we are now in a position to accelerate the migration of the cloud
version of one of our two leading offerings, Trisus Chargemaster following
successful early adoption. All of our existing Chargemaster Toolkit customers
are on track to have migrated to the Trisus Chargemaster by the end of
calendar 2022.
Our full Pharmacy suite continues to be developed and will now benefit from
the addition of the Sentry applications and expertise, with the two Pharmacy
teams now fully combined.
For our customers using any of the Craneware or Sentry existing pharmacy
offerings, we can now offer additional functionality through our Trisus
Pharmacy Financial Management (TRxFM) application and will soon launch two new
pharmacy applications for our hospital customers, generated by the combined
product team and representing an uplift potential to original contract values.
All of the acquired customers of Sentry are serviced utilising the Oracle
cloud architecture, therefore no technical integration is required, although
we will refresh the user interface to create the same look and feel as the
Trisus platform.
We have previously provided the metric of % of new sales relating to Trisus,
this is being replaced with the KPI: % ARR from the Cloud, reflecting that we
now have Sentry products that are already on the cloud and the sale of these
to our existing base is also a key part of our growth strategy. % of ARR
derived from the Cloud was 67% at 31 December 2021 (30 June 2021: 16%),
demonstrating considerable progress in the Period
2. To continue to enhance the capabilities of the platform through the
addition of new technology layers and applications - developed through
internal R&D, selective M&A and Third-Party Partnerships.
Expanding capabilities
We will continue to invest in expanding the capabilities of the platform,
developing additional applications and tools, to provide further actionable
insights that bring tangible benefits to our customers. The depth of our
product offering continues to grow through the mining of the proprietary and
regulatory data that we collect, identifying new ways the data can illuminate
and support decision making within the hospital provider environment. As we
expand our product offerings, make further acquisitions and add new customers,
the data assets available to mine for additional opportunity continues to grow
and provide significant barriers to entry for any new competitors.
Partnerships
We are now in a position to explore making the benefits of the Trisus platform
greater for hospitals by hosting third party application providers on Trisus.
These would typically be specialist application developers that provide single
point solutions in niche areas of interest to our customers.
M&A
While organic growth remains a priority, we continue to evaluate the market
and will continue to pursue strategically aligned companies that will
accelerate our growth strategy, although it is unlikely that any acquisitions
in the short-term will be significant relative to the scale of the new
enlarged group. We maintain the same four key acquisition criteria of which
target companies must fit into at least one, being:
(a) the addition of data sets;
(b) the extension of the customer base;
(c) the expansion of expertise; and
(d) the addition of applications suitable for the US hospital market.
In evaluating acquisition opportunities, the Board implements a strong
financial discipline seeking to maintain its prudent approach to preserving
balance sheet strength and efficiency for the long-term. Targets that are
profitable with recurring revenue models that provide earnings accretion
within the first 12 months of ownership are prioritised.
3. To grow our customer footprint, through increasing the attractiveness of
our offering and acquiring non-overlapping customers, which in turn provides
further cross-sale opportunities.
Each new customer extends our data assets that we can then mine to provide
better value to our customers through application development and actionable
insights. This reinforces our second growth pillar and by furthering the
attraction of the platform as a whole we encourage new customers to
investigate the benefits of joining the platform.
Customer retention has always been strong, and we continued to see our
customer retention rate remain high in the period above 90%.
Financial Review
On 12 July 2021, we completed the transformational acquisition of Sentry Data
Systems Inc ("Sentry"), a market leading provider of SaaS solutions which
simplify the complexity of pharmacy procurement, utilisation and regulatory
compliance. Sentry also provides business intelligence and SaaS analytics
solutions and consulting services.
In our trading update released on 31 January 2022, we were able to confirm the
scale of the enlarged Group with Sentry not yet contributing a full six months
of results, Group revenues have grown by 111% to $80.2m (H1 2021: $38m) H1and
adjusted EBITDA has increased by 78% to $23.7m (H1 2021: $13.3m). Adjusted
earnings per share has increased 34% to 43.5 cents per share (H1 2021: 32.5
cents per share).
Whilst proud of this new milestone in our evolution, we continue to remember
and remain in awe of the work our customers continue to do. They are on the
front line in the battle against the COVID 19 pandemic, Omicron wave and the
post pandemic recovery that brings another series of challenges to healthcare
providers worldwide. Supporting them and their teams, in the work they have
done and continue to do, remains our top priority.
The increased scale and newly enlarged portfolio of products mean we can do
even more to support our customers as they look beyond the impact of the
pandemic. The need for accurate financial data, supporting analytics and the
insights those analytics can bring has never been more important. Our
solutions can deliver real financial returns that can be re-invested by the
hospital to support the clinical care for their communities. For example, in
the period Craneware Group customers have earned in excess of $0.5 billion in
benefit from utilizing our 340B solutions to stretch scarce federal resources
as far as possible, reach more eligible patients and provide more
comprehensive services.
It is essential we continue to make the right investments in our future. As
such, and recognising the size of the Group post Sentry, we have further
increased our investment in R&D by 86% to $21.6m (H1 2021: $11.6m). The
level of this investment capitalised in the period has reduced in percentage
terms to 31% of the total investment, being $6.8m (H1 2021: $4.5m, 39%), the
balance of $14.8m (H1 2021: $7.1m) has been expensed as incurred. The
reduction in the percentage of R&D capitalised reflects the care we
continue to take to only capitalise projects that will bring future economic
benefit to the Group.
One of the ways we ensure our investments into R&D are benefitting our
strategy and delivering valuable future returns to the Group, is to monitor
the value of contracts sold for these new products once launched against the
costs that have been capitalised to date. I am pleased to confirm, in regard
to total costs we have capitalised in this and previous periods relating to
our Trisus developments (including applications that have yet to be brought to
market) we have contracted revenue that already covers approximately 70% of
this total.
We continue to maintain healthy cash reserves, which at the period end were
$41.7m, excluding restricted cash of $9.3m (H1 2021: $50.7m) and net debt of
$72.9m after the acquisition of Sentry and the associated acquisition costs of
$6.2m which were accrued in the prior year but paid in the current period.
Both figures are in line with the Board's expectations and represent a
comfortable level of debt for the business given our levels of EBITDA. From
our cash reserves, we have returned $7.2m to our shareholders through
dividends and made the $21.6m investments in R&D detailed above. We
continue to target operating cash conversion of 100% of adjusted EBITDA to
operating cash over a 12-month period. In the period we achieved 87% adjusted
cash conversion (including the acquisition costs detailed above) whilst below
our 100% 12 month target, is not unusual for the first half of the year and
are confident we will meet our target of 100% cash conversion for the full
fiscal year. In addition, we have continued to collect cash post the period
end, having already collected $23m related to the period.
Sentry Acquisition
The proposal to acquire Sentry was originally announced on 7 June 2021 (being
SDS Holdco, Inc., the ultimate holding company of Sentry Data Systems, Inc.)
and completed on 12 July 2021. The consideration for the acquisition (being on
a cash free / debt free basis) was $375m. Whilst we have completed our
provisional assessment of the fair value of the assets acquired and the
balance sheet presented includes these provisional amounts; $299.1m (as
adjusted) in cash and the balance by the issuance of 2,507,348 new ordinary
shares in the Company on 12 July 2021.
The cash consideration was funded from a combination of the Group's existing
cash resources, a new secured loan of $120m and the $187.3m net proceeds of
the share placing which completed in June 2021.
Underlying Business Model and Professional Services
The new contracts we sign with our customers provide a licence for the
customer to access specified products throughout their licence period. At
the end of an existing licence period, or at a mutually agreed earlier date,
we look to renew these contracts with our customers.
The existing contracts within Sentry are similar in their nature albeit are
often for a slightly shorter duration. In addition to the licence fees,
Sentry can also provide a number of transactional services to customers,
throughout the life of their underlying contracts. These transactional
services, whilst highly dependable, will see some variation period to period
dependent on volume of transactions.
Under the Group's business model, we recognise software licence revenue and
any minimum payments due from our 'other long term' contracts evenly over the
life of the underlying contract term. Transactional services are recognised
as we provide the service, and we are contractually able to invoice the
customer.
In addition to the licence revenues recognised in any year, we also expect
revenue to be recognised from providing services to our customers. These
revenues are usually recognised as we deliver the service to the customer, on
a percentage of completion basis.
The Omicron wave and the resulting shortages of available staff on site at
hospitals impacted our ability to deliver professional services in the
period. As professional services revenues are recognised as the service is
delivered, this impacted the underlying organic growth in the period. However,
we have retained our professional services capacity and as this short-term
impact reverses we are well positioned to return to growth in our professional
services delivery and associated revenue.
Annual Recurring Revenue
By renewing our underlying contracts, and ensuring we continue to deliver the
transactional services to our customers we sustain a highly visible recurring
revenue base, which means sales of new products to existing customers or sales
to new hospital customers add to this recurring revenue.
Following the acquisition of Sentry, we have introduced a new KPI of Annual
Recurring Revenue to supplement the existing financial KPI's we present.
With the increasing standardisation in how SaaS companies report, this KPI
will replace our historic three year visible revenue KPI. This KPI
demonstrates the annual value of licence and transactional revenues that are
subject to underlying contracts.
As at 31 December 2021, Annual Recurring Revenue had reached a new milestone
of approximately $165m (30 June 2021: $64.5m). In future periods, we will
introduce further KPI's to demonstrate how the underlying growth of the Group
is progressing from this foundation and to allow easier comparison between the
Group and its peers.
Functional Currency
We continue to report the results (and hold the cash reserves) of the Group in
US Dollars, whilst having approximately 20% percent of our costs, mainly our
UK employees and UK purchases, denominated in Sterling. The average exchange
rate for the Company during the reporting period was $1.36/£1 which compares
to $1.31/£1 in the corresponding period last year.
Dividend
The Board has resolved to pay an increased interim dividend of 12.5p (16.88
cents) per ordinary share on 15 April 2022 to those shareholders on the
register as at 25 March 2022 (FY21 Interim dividend 12p). The ex-dividend date
is 24 March 2022.
The interim dividend of 12.5p per share is capable of being paid in US dollars
subject to a shareholder having registered to receive their dividend in US
dollars under the Company's Dividend Currency Election, or who has
registered to do so by the close of business on 25 March 2022. The exact
amount to be paid will be calculated by reference to the exchange rate to be
announced on 25 March 2022. The interim dividend referred to above in US
dollars of 16.88 cents is given as an example only using the Balance Sheet
date exchange rate of $1.35/£1 and may differ from that finally announced.
Outlook
The combined scale and expertise of the enlarged Craneware Group provides the
potential for acceleration of ARR growth over the medium term, as we unlock
the considerable cross and upsell opportunity within our existing customer
base. Through our enlarged sales and marketing operation and unique breadth of
offering we are also well placed to secure increased market share as the US
healthcare industry continues its drive towards achieving greater value in
healthcare.
Whilst remaining cognisant of the challenges our customers continue to face;
the Company remains on-course to deliver results for the current year in line
with management's expectations.
With a strong balance sheet, high levels of recurring revenues, high customer
retention rates and an ARR of $165m as at 31 December 2021, we have a strong
financial foundation from which to accelerate growth and investment to fulfil
our potential, thereby increasing shareholder value.
We are delighted to see our first cross-sales within the enlarged Group which
we expect to accelerate once the COVID 19 headwinds fully dissipate. With an
expanded opportunity we look to the future with considerable excitement and
confidence as we work as one team to transform the business of US healthcare.
Keith Neilson Craig Preston
Chief Executive Officer
Chief Financial Officer
14 March 2022
14 March 2022
Consolidated Statement of Comprehensive Income
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
Notes $'000 $'000 $'000
Revenue 1 80,175 38,009 75,578
Cost of sales (9,839) (3,084) (5,373)
Gross profit 70,336 34,925 70,205
Other income 6 9 37
Operating expenses (62,528) (24,577) (56,507)
Net impairment charge on financial and contract assets (150) (383) (495)
Operating profit 7,664 9,974 13,240
Analysed as:
Adjusted EBITDA(1) 23,679 13,344 27,111
Share-based payments (1,013) (1,048) (2,141)
Depreciation of property, plant and equipment (1,511) (732) (1,403)
Amortisation of intangible assets - other (2,653) (1,307) (3,840)
Amortisation of intangible assets - acquired intangibles (8,919) - -
Exceptional costs(2) (1,919) (283) (6,487)
Finance income 1 - 1
Finance expense (1,431) (45) (76)
Profit before taxation 6,234 9,929 13,165
Tax charge on profit on ordinary activities (1,514) (1,482) (260)
Profit for the period attributable to owners of the parent 4,720 8,447 12,905
Other comprehensive income
Items that may be reclassified subsequently to profit or loss
Currency Translation Reserve movement 27 (25) (126)
Total items that may be reclassified subsequently to profit or loss 27 (25) (126)
Total comprehensive income attributable to owners of the parent 4,747 8,422 12,779
(1)See note 15 for explanation of Alternative Performance Measures.
(2 )Exceptional items relate to legal and professional fees associated with a
successful acquisition and related integration costs. (FY21: legal and
professional fees associated with an aborted potential acquisition in H1 2021
and a successful acquisition completed post year end and its associated share
placing.)
Earnings per share for the period attributable to equity holders
- Basic ($ per share) 3 0.135 0.315 0.481
- *Adjusted Basic ($ per share)(1) 3 0.435 0.325 0.690
- Diluted ($ per share) 3 0.133 0.311 0.475
- *Adjusted Diluted ($ per share)(1) 3 0.430 0.321 0.681
( )
Consolidated Statement of Changes in Equity
Share Capital Share Premium Capital Redemption Reserve Merger Reserve Other Reserves Retained Earnings Total
$'000 $'000 $'000 $'000 $'000 $'000 $'000
At 1 July 2020 536 21,097 9 - 4,148 42,605 68,395
Total comprehensive income - profit for the period - - - - - 8,447 8,447
Total other comprehensive income - - - - - (25) (25)
Transactions with owners
Share-based payments - - - - 1,003 - 1,003
Dividend - - - - - (5,329) (5,329)
At 31 December 2020 536 21,097 9 - 5,151 45,698 72,491
Total comprehensive income - profit for the period - - - - - 4,458 4,458
Total other comprehensive expense - - - - - (101) (101)
Transactions with owners
Share-based payments - - - - 329 - 329
Share placing 88 - - 186,993 - - 187,081
Purchase of own shares through EBT - - - - - (422) (422)
Deferred tax taken directly to equity - - - - - 1,212 1,212
Impact of share options and awards exercised/lapsed - - - - (752) 354 (398)
Dividend - - - - - (4,371) (4,371)
At 30 June 2021 624 21,097 9 186,993 4,728 46,828 260,279
Total comprehensive income - profit for the period - - - - - 4,720 4,720
Total other comprehensive income - - - - - 27 27
Transactions with owners
Share-based payments - - - - 884 - 884
Share issue 34 75,871 - (12) - - 75,893
Impact of share options and awards exercised/lapsed - - - - - (311) (311)
Dividend - - - - - (7,227) (7,227)
At 31 December 2021 658 96,968 9 186,981 5,612 44,037 334,265
Consolidated Balance Sheet as at 31 December 2021
unaudited unaudited audited
H1 2022 H1 2021 FY2021
Notes $'000 $'000 $'000
ASSETS
Non-Current Assets
Property, plant and equipment 10,608 3,170 2,552
Intangible assets - goodwill 4 243,368 11,188 11,188
Intangible assets - acquired intangibles 4 189,109 - -
Intangible assets - other 4 43,179 28,881 31,922
Trade and other receivables 5 3,673 4,074 5,427
Deferred Tax - 2,408 5,459
489,937 49,721 56,548
Current Assets
Trade and other receivables 5 68,349 21,896 19,435
Cash and cash equivalents 41,696 50,721 235,617
Restricted cash 9,338 - -
Total Cash and cash equivalents 9 51,034 50,721 235,617
119,383 72,617 255,052
Total Assets 609,320 122,338 311,600
EQUITY AND LIABILITIES
Non-Current Liabilities
Borrowings 7 107,081 - -
Leased property 2,223 1,602 1,148
Leased equipment 713 - -
Deferred tax 44,498 - -
Other provisions 893 - 764
155,408 1,602 1,912
Current Liabilities
Borrowings 7 7,491 - -
Deferred income 86,079 37,015 33,670
Current tax liabilities - 2,203 -
Trade and other payables 6 26,077 9,027 15,739
119,647 48,245 49,409
Total Liabilities 275,055 49,847 51,321
Equity
Share capital 8 658 536 624
Share premium account 96,968 21,097 21,097
Capital redemption reserve 9 9 9
Merger reserve 186,981 - 186,993
Other reserves 5,612 5,151 4,728
Retained earnings 44,037 45,698 46,828
Total Equity 334,265 72,491 260,279
Total Equity and Liabilities 609,320 122,338 311,600
Consolidated Statement of Cash Flow for the six months ended 31 December 2021
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
Notes $'000 $'000 $'000
Cash flows from operating activities
Cash generated from 9 12,593 13,371 26,711
operations
Tax paid (2,511) (77) (3,174)
Net cash from operating activities 10,082 13,294 23,537
Cash flows from investing activities
Acquisition of subsidiary, net of cash acquired (293,493) - -
Purchase of plant and equipment (249) (104) (159)
Capitalised intangible assets (6,847) (4,612) (10,167)
Interest received 1 1 1
Net cash used in investing activities (300,588) (4,715) (10,325)
Cash flows from financing activities
Dividends paid to company shareholders (7,227) (5,329) (9,700)
Shares issued for cash - - 187,244
Paid up share capital - - 88
Share issue professional fees (263) - -
Proceeds from borrowings 120,000 - -
Loan arrangement fees - - (1,692)
Repayment of borrowings (4,000) - -
Interest on bank loan (1,341) - -
Purchase of own shares by EBT - - (422)
Leased property payments (1,246) (380) (964)
Net cash used in financing activities 105,923 (5,709) 174,554
Net (decrease)/increase in cash and cash equivalents (184,583) 187,766
2,870
Cash and cash equivalents at the start of the period 235,617 47,851
47,851
Cash and cash equivalents at the end of the period 51,034 50,721 235,617
Notes to the Financial Statements
1. Revenue
The chief operating decision maker has been identified as the Board of
Directors. The Group revenue is derived almost entirely from the sale of
software licences, professional services (including installation) and
transactional fees to hospitals and affiliated pharmacies within the United
States of America. Consequently, the Board has determined that Group supplies
only one geographical market place and as such revenue is presented in line
with management information without the need for additional segmental
analysis. All of the Group's assets are located in the United States of
America with the exception of the Parent Company's, the net assets of which
are disclosed separately on the Company Balance Sheet and are located in the
United Kingdom.
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
$'000 $'000 $'000
Software licencing 71,483 30,136 61,115
Professional services 6,211 7,873 14,463
Transactional fees 2,481 - -
Total revenue 80,175 38,009 75,578
Software licensing and professional services are recognised over time.
Transactional fees are recognised at a point in time.
2. Business combination
On 12 July 2021, the Group acquired 100% of the voting rights of SDS Holdco,
Inc., the ultimate holding company of Sentry Data Systems, Inc. ('Sentry'), a
leader in the pharmacy procurement, compliance and utilisation management,
based in Florida, USA. For further information on the reasons for the
acquisition see Note 25 of the annual report for the year ended 30 June 2021.
The aggregate consideration for the acquisition of Sentry on a cash free/ debt
free basis subject to an adjustment against a benchmark level of working
capital on the date of acquisition as calculated and determined in accordance
with the terms of the agreement relating to the acquisition.
The deal was funded by $299.1m (as adjusted) of cash and $75.9m raised via the
issue of 2,507,348 new ordinary shares at fair value on 12 July 2021 (measured
using the closing market price of the Company's ordinary shares on that
date). The cash consideration was funded from the Group's existing cash
resources, $120m from a new debt facility and $187.3m net proceeds from a
share placing completed in June 2021.
Details of the purchase consideration, net assets acquired and goodwill, are
as follows:
$'000
Cash paid (net of working capital adjusted) 299,100
Shares issued (fair value) 75,905
Total purchase consideration 375,005
The provisional fair values for assets and liabilities recognised as a result
of the acquisition are as follows:
Provisional
Fair value
$'000
Non-Current assets
Property, plant and equipment 9,499
Intangible assets - customer relations 151,000
Intangible asset - proprietary software 42,028
Intangible assets - trademarks 5,000
Intangible assets - other 6,831
Other contract assets 521
Total non-current assets 214,879
Current assets
Trade and other receivables 33,088
Cash and cash equivalents 3,728
Restricted cash 1,879
Total current assets 38,695
Non-current liabilities
Leased property > 1 year 1,540
Leased equipment > 1 year 1,146
Deferred tax 49,957
Total non-current liabilities 52,643
Current liabilities
Deferred income 45,437
Trade and other payables 12,669
Total current liabilities 58,106
Net identifiable assets acquired 142,825
Add: goodwill 232,180
Total consideration 375,005
The goodwill is attributable to Sentry's strong position in the market and
synergies expected to arise after the company's acquisition of these new
subsidiaries.
The fair value of the acquired customer list and customer contracts of $151m,
proprietary software of $42.0 and trademarks of $5.0m are provisional pending
receipt of the final valuation for these assets. Final fair values will be
reported in the Group's Annual Report for the year ending 30 June 2022.
Deferred tax of $37.8m, $10.5m and $1.3m has been provided respectively in
relation to these adjustments.
Acquisition related costs of $1.9m are included within exceptional costs in
profit and loss.
The fair value of trade and other receivables is $33.1m and includes trade
receivables with a fair value of $9.5m. The gross contractual amount for
trade receivables due is $12.7m of which $3.2m is expected to be
uncollectible. Also included within trade and other receivables is the
enforceable, non-cancelable unbilled portion of annual software and service
contracts with a fair value of $18.8m.
Sentry contributed revenue of $44.9m and net profit of $1.1m to the Group for
the period from 13 July 2021 to 31 December 2021. If the acquisition had
occurred on 1 July 2021, consolidated revenue and consolidated profit after
tax for the half year ended 31 December 2021 would have been $82.8m and $4.8m
respectively.
3. Earnings per Share
The calculation of basic and diluted earnings per share is based on the
following data:
Weighted average number of shares
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
No. of Shares No. of Shares No. of Shares
000s 000s 000s
Weighted average number of Ordinary Shares for the purpose of basic earnings 35,034 26,827 26,811
per share
Effect of dilutive potential Ordinary Shares: share options and LTIPs 412 346 374
Weighted average number of Ordinary Shares for the purpose of diluted earnings 35,446 27,173 27,185
per share
The Group has one category of dilutive potential Ordinary shares, being those
granted to Directors and employees under the share schemes.
Shares held by the Employee Benefit Trust are excluded from the weighted
average number of Ordinary shares for the purposes of basic earnings per
share.
Profit for period
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
$000's $'000s $000's
Profit for the period attributable to equity holders of the parent 4,720 8,447 12,905
Aborted share placing costs (tax adjusted) - 283 386
Acquisition and associated share placing costs (tax adjusted) 1,321 - 5,210
Acquisition integration costs (tax adjusted) 290 - -
Amortisation of acquired intangibles 8,919 - -
Adjusted profit for the period attributable to equity holders of the parent 15,250 8,730 18,501
Basic earnings per share are calculated by dividing the profit attributable to
equity holders of the Company by the weighted average number of shares in
issue during the period.
For diluted earnings per share, the weighted average number of Ordinary shares
calculated above is adjusted to assume conversion of all dilutive potential
Ordinary shares.
Earnings per share
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
cents cents cents
Basic EPS 13.5 31.5 48.1
Diluted EPS 13.3 31.1 47.5
Adjusted basic EPS 43.5 32.5 69.0
Adjusted diluted EPS 43.0 32.1 68.1
4. Intangible assets
Goodwill Customer Relationships Proprietary Software Development Costs Computer Software Total
Trademarks
$'000 $'000 $'000 $'000 $'000 $'000 $'000
Cost
At 1 July 2021 11,438 2,964 3,043 - 42,976 1,004 61,425
Additions - - - - 6,123 956 7,079
Acquisition of subsidiary 232,180 151,000 42,028 5,000 - 6,831 437,039
At 31 December 2021 243,618 153,964 45,071 5,000 49,099 8,791 505,543
Accumulated amortisation and impairment
At 1 July 2021 250 2,964 3,043 - 11,324 734 18,315
Amortisation charge - 4,719 3,940 260 2,027 626 11,572
At 31 December 2021 250 7,683 6,983 260 13,351 1,360 29,887
Net book value at 31 December 2021 243,368 146,281 38,088 4,740 35,748 7,431 475,656
Net book value at 30 June 2021 11,188 - - - 31,652 270 43,110
5. Trade and other receivables
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
$'000 $'000 $'000
Trade receivables 43,161 17,411 16,450
Less: provision for impairment of trade receivables (5,584) (2,190) (2,270)
Net trade receivables 37,577 15,211 14,180
Unbilled contract revenue 18,725 - -
Other receivables 3,348 698 302
Current tax receivable 2,723 - 278
Prepayments and accrued income 3,441 3,641 4,090
Deferred contract costs 6,208 6,410 6,012
72,022 25,970 24,862
Less non-current prepaid loan arrangement fees - - (1,692)
Less non-current deferred contract costs (3,673) (4,074) (3,735)
Trade and other receivables 68,349 21,896 19,435
------There is no material difference between the fair value of trade and
other receivables and the book value stated above. All amounts included within
trade and receivables are classified as financial assets at amortised cost.
6. Trade and other payables
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
$'000 $'000 $'000
Trade payables 5,545 1,620 1,844
Lease creditor due < 1 year 1,272 1,066 1,053
Social security and PAYE 2,452 1,903 1,556
Other payables 1,016 71 50
Amounts held on behalf of customers 8,867 - -
Accruals 6,925 4,367 10,808
Advanced payments - - 428
Trade and other payables 26,077 9,027 15,739
No derivatives have been entered into in the current reporting period. No
other assets or liabilities have been measured at fair value. Trade and other
payables are classified as financial liabilities at amortised cost.
7. Borrowings
In June 2021, the Group entered into a new debt facility to finance the
purchase of Sentry Data Systems, Inc. The total available amount under the
facility is $140m, of which $120m was drawn down on 12 July 2021.
The debt facility comprises a term loan of $40m which is repayable in
quarterly installments over 5 years up to 30 June 2026, and a revolving loan
facility of $80m which expires on 7 June 2024. The Group has the ability to
extend the revolving loan facility for an additional two year term.
Interest is charged on the facility on a daily basis at margin and compounded
reference rate. The margin rate is fixed at 2.55% for the first 6 months of
the facility term.
The facility agreement and is secured by a Scots law floating charge granted
by the Company, an English law debenture granted by the Company and a New York
law security agreement to which the Company and certain of its subsidiaries
are parties. The securities granted by the Company and the relevant
subsidiaries provide security over all assets of the Company and specified
assets of the Group.
The contractual maturity of the Group's borrowings at the period end were as
follows:
Less than Between Between Total
1 year 1 to 2 years 2 to 5 years
As at 31 December 2021 $'000 $'000 $'000 $'000
Term loan 8,000 8,000 20,000 36,000
Revolving facility - - 80,000 80,000
Arrangement fees (509) (487) (432) (1,428)
Borrowing facilities 7,491 7,513 99,568 114,572
Arrangement fees paid in advance of the setting up of the facility are being
recognised over the life of the facility in operating costs.
Loan covenants
Under the facilities the Group is required to meet quarterly covenants tests
in respect of:
a) Adjusted leverage which is the ratio of total net debt on the last day of
the relevant period to adjusted EBITDA
b) Cash flow cover which is the ratio of cashflow to net finance charges in
respect of the relevant period.
The Group complied with these ratios throughout the reporting period.
Financing arrangements
The Group's undrawn borrowing facilities were as follows:
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
$'000 $'000 $'000
Term loan - - 40,000
Revolving facility 20,000 - 100,000
Undrawn borrowing facilities 20,000 - 140,000
8. Called up share capital
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
Number $'000 Number $'000 Number $'000
Authorised
Equity share capital
Ordinary shares of 1p each 50,000,000 1,014 50,000,000 1,014 50,000,000 1,014
Allotted called-up and fully paid
Equity share capital
Ordinary shares of 1p each 35,526,539 658 26,826,539 536 33,019,191 624
During the period ended 31 December 2021, shares were allotted as part of the
consideration for the acquisition of Sentry Data Systems, Inc. as described in
Note 2.
9. Consolidated Cash Flow generated from operating activities
Reconciliation of profit before taxation to net cash inflow from operating
activities:
unaudited unaudited audited
H1 2022 H1 2021 FY 2022
$'000 $'000 $'000
Profit before taxation 6,234 9,929 13,165
Finance income (1) - (1)
Finance expense 1,431 45 76
Depreciation on plant and equipment 1,511 732 1,403
Amortisation of intangible assets - other 2,653 1,307 3,840
Amortisation of intangible assets - acquired intangibles 8,919 - -
Share-based payments 1,013 1,048 2,141
FX on non-cash items - - (136)
Movements in working capital:
(Increase)/Decrease in trade and other receivables (15,343) (1,051) 2,026
Increase/(Decrease) in trade and other payables 6,176 1,361 4,197
Cash generated from operations 12,593 13,371 26,711
Total cash and cash equivalents at 31 December 2021 includes restricted cash
of $9.3m which relates to amounts held on behalf of customers as part of
services provided in connecting them to their contract pharmacy network.
These amounts are generally held by the Group for less than 30 days. The
Group retains fees from the restricted cash accounts for services provided to
customers in managing the transfer of cash and for reconciliation services.
10. Basis of Preparation
The interim financial statements are unaudited and do not constitute statutory
accounts as defined in S435 of the Companies Act 2006. These statements have
been prepared applying accounting policies that were applied in the
preparation of the Group's consolidated accounts for the year ended 30th June
2021 and the changes outlined below in Note 13. Those accounts, with an
unqualified audit report, have been delivered to the Registrar of Companies.
The interim financial statements have been prepared on a going concern basis.
The Group's activities and an overview of the development of its products,
services and the environment in which it operates together with an update on
the Group's financial performance and position are set out in the Financial
Review. Despite the ongoing uncertainties and challenges caused by COVID-19
pandemic, the Group is profitable, cash generative and the half year trading
results are in line with expectations. An overview of the impact of the
COVID-19 pandemic on the Group in the period are contained in the Strategic
Report, and details were also contained in the Group's Annual Report and
Financial Statements for the year ended 30 June 2021. The Board continues to
carefully monitor the impact of the COVID-19 pandemic on the operations of the
Group. The Viability Statement and the Board's Going Concern assessment
contained the Annual Report for the year ended 30 June 2021 are still
considered to be appropriate by the Board. The SaaS business model with its
underlying long-term contracts as described earlier in the Financial Review,
high levels of associated cash generation and long-term focus on customer
success provides a foundation of revenue for future periods. This foundation
of contracted revenue forms the basis of the scenarios considered but the
Directors in making this assessment.
The Directors, having made suitable enquiries and analysis of the interim
financial statements, including the consideration of: net cash reserves;
continued cash generation; compliance with loan facility covenants; and
Annuity SaaS business model; have determined that the Group has adequate
resources to continue in business for the foreseeable future and that it is
therefore appropriate to adopt the going concern basis in preparing the
interim financial statements.
11. Segmental Information
The Directors consider that the Group operates in predominantly one business
segment, being the creation of software sold entirely to the US Healthcare
Industry, and that there are therefore no additional segmental disclosures to
be made in these financial statements.
12. Risks and uncertainties
The principal risks and uncertainties, as set out on pages 14 to 17 of the
Annual Report for the year ended 30 June 2021, remain unchanged. The
unchanged risks are:
· Data and cyber security
· Intellectual property risk
· US Healthcare: Complexity, evolution and reform
· Regulatory environment
· Political and microeconomic changes
· Market and customer consolidation
· Competitive landscape
· Acquisition risk
The Directors regularly review these risks and uncertainties and appropriate
actions are taken to manage them. Included within the Strategic Report is
more detail on the outlook for the Group for the remaining six months of the
year.
13. Changes to Significant Accounting Policies, Judgements and Estimates
The accounting policies, significant judgements and key sources of estimation
applied in these interim financial statements are the same as those applied in
the Group's consolidated financial statements as at and for the year ended 30
June 2021 except as detailed below:
Borrowings
Borrowings represent bank loans, initially measured at fair value net of
transaction costs and subsequently measured at amortised cost, using the
effective interest rate method.
Finance charges are accounted for in profit or loss over the term of the loan.
14. Availability of announcement and Half Yearly Financial Report
Copies of this announcement are available on the Company's website,
www.craneware.com (http://www.craneware.com) . Copies of the Interim Report
will be posted to shareholders, downloadable from the Company's website and
available from the registered office of the Company shortly.
15. Alternative performance measures
The Group's performance is assessed using a number of financial measures which
are not defined under IFRS and are therefore non-GAAP (alternative)
performance measures.
The Directors believe these measures enable the reader to focus on what the
Group regard as a more reliable indicator of the underlying performance of the
Group since they exclude items which are not reflective of the normal course
of business, accounting estimates and non-cash items. The adjustments made
are consistent and comparable with other similar companies.
These are as follows:
Adjusted EBITDA
Adjusted EBITDA refers to earnings before interest, tax, depreciation,
amortisation, exceptional items and share based payments.
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
$'000 $'000 $'000
Operating profit 7,664 9,974 13,240
Depreciation of property, plant and equipment 1,511 732 1,403
Amortisation of intangible assets - other 2,653 1,307 3,840
Amortisation of intangible assets - acquired intangibles 8,919 - -
Share based payments 1,013 1,048 2,141
Exceptional items - aborted share placing - 283 283
Exceptional items - acquisition and associated share placing 1,573 - 6,204
Exceptional items - integration costs 346 - -
Adjusted EBITDA 23,679 13,344 27,111
Adjusted earnings per share (EPS)
Adjusted earnings per share (EPS) calculations allow for the tax adjusted
acquisition costs and share related transactions together with amortisation on
acquired intangibles via business combinations. See Note 3 for the
calculation.
Operating cash conversion
Operating cash conversion is calculated as cash generated from operations (as
per Note 9), adjusted to exclude cash payments for exceptional items, divided
by adjusted EBITDA.
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
$'000 $'000 $'000
Cash generated from operations (note 9) 12,593 13,371 26,711
Total exceptional items 1,919 283 6,487
Accrued exceptional items at the start of the period paid in the current 5,509 - -
period
Accrued exceptional items at the end of the period (39) - (5,509)
Trade payable exceptional items at the start of the period paid in the current 683 - -
period
Trade payables cash exceptional items at the end of the period (21) - (683)
Cash generated from operations before exceptional items 20,644 13,654 27,006
Adjusted EBITDA 23,679 13,344 27,111
Operating cash conversion 87% 102.3% 99.6%
Adjusted PBT
Adjusted PBT refers to profit before tax adjusted for exceptional items and
amortisation of acquired intangibles.
unaudited unaudited audited
H1 2022 H1 2021 FY 2021
$'000 $'000 $'000
Profit before taxation 6,234 9,929 13,165
Amortisation of intangible assets - acquired intangibles 8,919 - -
Exceptional items - aborted share placing - 283 283
Exceptional items - acquisition and associated share placing 1,573 - 6,204
Exceptional items - integration costs 346 - -
Adjusted PBT 17,072 10,212 19,652
Net Debt
New Debt refers to net balance of short term borrowings, long term borrowings
and cash and cash equivalents (excluding restricted cash).
Annual Recurring Revenue
Annual Recurring Revenue includes the annual value of licence and transaction
revenues as at 31 December 2021 that are subject to underlying contracts.
% Annual Recurring Revenue from the Cloud
% Annual Recurring Revenue from the Cloud is the Annual Recurring Revenue as
described above relating specifically to cloud-based products expressed as a %
of total Annual Recurring Revenue.
Revenue Growth
Revenue Growth is the increase in Revenue in the current period compared to
the previous period expressed as a % of the previous period Revenue.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IR GPUPAWUPPGUW